1. Home
  2. SCLX vs BEDU Comparison

SCLX vs BEDU Comparison

Compare SCLX & BEDU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCLX
  • BEDU
  • Stock Information
  • Founded
  • SCLX 2011
  • BEDU 1994
  • Country
  • SCLX United States
  • BEDU United Kingdom
  • Employees
  • SCLX N/A
  • BEDU N/A
  • Industry
  • SCLX Biotechnology: Pharmaceutical Preparations
  • BEDU Other Consumer Services
  • Sector
  • SCLX Health Care
  • BEDU Real Estate
  • Exchange
  • SCLX Nasdaq
  • BEDU Nasdaq
  • Market Cap
  • SCLX 51.3M
  • BEDU 44.9M
  • IPO Year
  • SCLX N/A
  • BEDU 2017
  • Fundamental
  • Price
  • SCLX $4.06
  • BEDU $1.56
  • Analyst Decision
  • SCLX Strong Buy
  • BEDU
  • Analyst Count
  • SCLX 4
  • BEDU 0
  • Target Price
  • SCLX $396.67
  • BEDU N/A
  • AVG Volume (30 Days)
  • SCLX 103.2K
  • BEDU 18.8K
  • Earning Date
  • SCLX 05-12-2025
  • BEDU 04-29-2025
  • Dividend Yield
  • SCLX N/A
  • BEDU N/A
  • EPS Growth
  • SCLX N/A
  • BEDU N/A
  • EPS
  • SCLX N/A
  • BEDU N/A
  • Revenue
  • SCLX $56,590,000.00
  • BEDU $231,461,038.00
  • Revenue This Year
  • SCLX $115.30
  • BEDU N/A
  • Revenue Next Year
  • SCLX $73.33
  • BEDU N/A
  • P/E Ratio
  • SCLX N/A
  • BEDU N/A
  • Revenue Growth
  • SCLX 21.07
  • BEDU N/A
  • 52 Week Low
  • SCLX $5.80
  • BEDU $1.35
  • 52 Week High
  • SCLX $80.50
  • BEDU $2.42
  • Technical
  • Relative Strength Index (RSI)
  • SCLX 24.27
  • BEDU 45.13
  • Support Level
  • SCLX $3.60
  • BEDU $1.47
  • Resistance Level
  • SCLX $7.64
  • BEDU $1.78
  • Average True Range (ATR)
  • SCLX 1.21
  • BEDU 0.19
  • MACD
  • SCLX -0.37
  • BEDU -0.02
  • Stochastic Oscillator
  • SCLX 6.67
  • BEDU 14.29

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

About BEDU Bright Scholar Education Holdings Limited each representing four

Bright Scholar Education Holdings Ltd operates as an education service provider. It is engaged in the provision of education services, including complementary education services, operation services for domestic schools, and education programs and services including independent schools and colleges in United Kingdom (the UK) and the United States (the U.S.) Kingdom. It nearly eight overseas school located in the United Kingdom and the United States. It has three reportable segments, including Overseas Schools, Complementary Education Services, and K-12 Operation Services. Key revenue is generated from Overseas Schools. From a geographical perspective: Key revenue is generated from China following UK, U.S., Canada and Singapore.

Share on Social Networks: